Investors are always looking for stocks that are poised to beat at earnings season and Intra-Cellular Therapies, Inc. (ITCI Quick QuoteITCI - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Intra-Cellular Therapies is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ITCI in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.03 per share for ITCI, compared to a broader Zacks Consensus Estimate of a loss of $1.05 per share. This suggests that analysts have very recently bumped up their estimates for ITCI, giving the stock a Zacks Earnings ESP of +2.14% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that ITCI has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Intra-Cellular Therapies, and that a beat might be in the cards for the upcoming report.